Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis

Status:
Withdrawn

Trial end date:
2018-03-01

Target enrollment:

Participant gender:

To evaluate efficacy and safety of BGG492 versus placebo on moderate to severe spasticity due to multiple sclerosis

Phase 2

Novartis Pharmaceuticals